News Related to Janus Kinase

Related coverage linked through entity extraction aliases.

Pharma Faces $200-300 Billion Patent Cliff Through 2032 as Blockbusters Lose Exclusivity

Feb 16, 2026

The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.

Takeda's Zasocitinib Meets Phase 3 Endpoints in Plaque Psoriasis, Pediatric Trial Underway

Dec 19, 2025

Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.